Compare ATLX & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATLX | OVID |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.7M | 126.8M |
| IPO Year | N/A | 2017 |
| Metric | ATLX | OVID |
|---|---|---|
| Price | $5.21 | $1.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $12.00 | $3.50 |
| AVG Volume (30 Days) | 635.0K | ★ 1.6M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $180,454.00 | ★ $6,610,000.00 |
| Revenue This Year | $22,084.55 | $1,077.56 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 945.89 |
| 52 Week Low | $3.54 | $0.24 |
| 52 Week High | $8.25 | $2.01 |
| Indicator | ATLX | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 54.06 |
| Support Level | $4.77 | $1.59 |
| Resistance Level | $5.33 | $1.87 |
| Average True Range (ATR) | 0.36 | 0.13 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 91.00 | 71.55 |
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project located in Minas Gerais State in Brazil. The company intends to produce and sell lithium concentrate, a key ingredient for the battery supply chain. It intends to mine and then process its lithium-containing ore to produce lithium concentrate (also known as spodumene concentrate), a key ingredient for the battery supply chain.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.